Bioaffinity Technologies Inc (BIAF) Stock Price, Quote & News

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 210 698 5334

Website: www.bioaffinitytech.com

Address:

3300 Nacogdoches Road, Suite 216, San Antonio, United States

Jmofo Jul. 16 at 8:27 PM

$BIAF at this point it’s just annoying, why can it not break .34 / .35

0 · Reply

Lifeis Jul. 16 at 7:57 PM

$BIAF Needs to be at $1 on August 6th ? Yes..... No ????

2 · Reply

MrBigMike Jul. 16 at 7:18 PM

$BIAF any news released or just organic pump ?

0 · Reply

AvgNightmare Jul. 16 at 6:59 PM

$BIAF Guess I'll buy more. This thing needs a push.

0 · Reply

dawsondesign Jul. 16 at 6:30 PM

$BIAF big green candle incoming

0 · Reply

miraclehunter Jul. 16 at 5:56 PM

$BIAF can I get a double? 🙏

0 · Reply

mcrotary Jul. 16 at 5:53 PM

$BIAF looking strong by the minute

0 · Reply

dawsondesign Jul. 16 at 5:15 PM

$BIAF wants .34

0 · Reply

Danny_vdw74 Jul. 16 at 5:08 PM

$SYTA. $BIAF VANCOUVER, BC, July 16, 2025 /CNW/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that its flagship device, the Siyata SD7, has earned the "Verizon Frontline Verified" designation, joining an elite group of solutions vetted and approved for use by first responders operating on the Verizon Frontline network.

0 · Reply

Havoc1649 Jul. 16 at 4:56 PM

$BIAF heavy on the buy side (of the real buyers) near as I can tell today. There’s a Market Maker(s) yet again illegally trading it sideways. I’m so sick of this s#it. They are undercutting the Ask in 200 share increments triggering an up and down movement, constantly churning it to make money off the spread. These firms need to be destroyed and those running these scams imprisoned. I know for a fact the SEC is aware of this on this particular security. If they will do anything about it is the question.

0 · Reply

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jun 26, 2025, 9:00 AM EDT - 20 days ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 24, 2025, 9:00 AM EDT - 22 days ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 11, 2025, 9:00 AM EDT - 5 weeks ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

May 28, 2025, 9:00 AM EDT - 7 weeks ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 20, 2025, 9:00 AM EDT - 2 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 15, 2025, 8:30 AM EDT - 2 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

May 8, 2025, 9:00 AM EDT - 2 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 7, 2025, 1:15 PM EDT - 2 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:00 PM EDT - 2 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 6, 2025, 10:30 AM EDT - 2 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 9:25 AM EDT - 2 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

Apr 17, 2025, 9:15 AM EDT - 3 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Mar 31, 2025, 9:28 AM EDT - 3 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 26, 2025, 9:00 AM EDT - 4 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 19, 2025, 9:00 AM EDT - 4 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 13, 2025, 9:00 AM EDT - 4 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 6, 2025, 8:00 AM EST - 4 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Feb 26, 2025, 12:10 PM EST - 5 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 5 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 5 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 5 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Jan 22, 2025, 8:00 AM EST - 6 months ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 13, 2025, 8:00 AM EST - 6 months ago

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Jan 10, 2025, 9:00 AM EST - 6 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

Dec 17, 2024, 8:00 AM EST - 7 months ago

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

Dec 12, 2024, 8:00 AM EST - 7 months ago

bioAffinity Technologies Set for Continued Expansion in 2025

Nov 14, 2024, 8:00 AM EST - 8 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

Nov 4, 2024, 8:00 AM EST - 9 months ago

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

Oct 30, 2024, 8:00 AM EDT - 9 months ago

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

Oct 21, 2024, 11:39 AM EDT - 9 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 21, 2024, 10:45 AM EDT - 9 months ago

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 2:57 PM EDT - 9 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 12:45 PM EDT - 9 months ago

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 16, 2024, 8:00 AM EDT - 9 months ago

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

Oct 10, 2024, 8:00 AM EDT - 9 months ago

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Oct 9, 2024, 8:00 AM EDT - 10 months ago

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Sep 18, 2024, 8:00 AM EDT - 10 months ago

Peer-Reviewed Study: bioAffinity Technologies' CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Aug 23, 2024, 5:15 PM EDT - 11 months ago

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

Aug 14, 2024, 9:25 AM EDT - 1 year ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

Aug 5, 2024, 2:00 PM EDT - 1 year ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 5, 2024, 1:17 PM EDT - 1 year ago

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 2, 2024, 10:00 AM EDT - 1 year ago

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 2, 2024, 9:25 AM EDT - 1 year ago

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Jul 12, 2024, 9:35 AM EDT - 1 year ago

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 9, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

Jul 5, 2024, 9:00 AM EDT - 1 year ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIVI

Jun 12, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

May 15, 2024, 9:15 AM EDT - 1 year ago

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

May 2, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies News Update

Jmofo Jul. 16 at 8:27 PM

$BIAF at this point it’s just annoying, why can it not break .34 / .35

0 · Reply

Lifeis Jul. 16 at 7:57 PM

$BIAF Needs to be at $1 on August 6th ? Yes..... No ????

2 · Reply

MrBigMike Jul. 16 at 7:18 PM

$BIAF any news released or just organic pump ?

0 · Reply

AvgNightmare Jul. 16 at 6:59 PM

$BIAF Guess I'll buy more. This thing needs a push.

0 · Reply

dawsondesign Jul. 16 at 6:30 PM

$BIAF big green candle incoming

0 · Reply

miraclehunter Jul. 16 at 5:56 PM

$BIAF can I get a double? 🙏

0 · Reply

mcrotary Jul. 16 at 5:53 PM

$BIAF looking strong by the minute

0 · Reply

dawsondesign Jul. 16 at 5:15 PM

$BIAF wants .34

0 · Reply

Danny_vdw74 Jul. 16 at 5:08 PM

0 · Reply

Havoc1649 Jul. 16 at 4:56 PM

0 · Reply

Tom678 Jul. 16 at 4:19 PM

$BIAF something is brewing

0 · Reply

mcrotary Jul. 16 at 3:22 PM

$BIAF might surprise

0 · Reply

Havoc1649 Jul. 16 at 3:14 PM

$BIAF someone put up 200 shares $.02 under the ask. The manipulation is ridiculous.

0 · Reply

Um8a123 Jul. 16 at 3:13 PM

$BIAF Lets go!!

0 · Reply

Jmofo Jul. 16 at 3:08 PM

$BIAF looking ready to run 🙂

0 · Reply

CoachBaileyCooper Jul. 16 at 3:02 PM

$BIAF this will get worse before it gets better. If you're new to this stock, market makers do everything they can to keep it at this level whenever it pumps. 😉 So be patient and HODL. Incoming R/S vote July 25th (board is recommending) Needs profitability shown in future earnings on the new CY-Path Lung, and topical products. Then moon and back, then possibly above $6 per share. That's my price target. It could moon above $20-30 if other pharmaceutical companies partner with them.

0 · Reply